Search research articles
Contact Us
Filters
Showing results (101-110 of 130) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Nature Genetics
|
September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation
Sylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 20, 2025
Epigenome-Wide Analysis Identifies Pollution-Sensitive Loci in Fibrotic Interstitial Lung Disease
Gillian C Goobie, Najmeh Assadinia, Chen Xi Yang, et al.
Blood
|
April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Blood
|
February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma
Catherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology
|
August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 130) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Nature Genetics
|
September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation
Sylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 20, 2025
Epigenome-Wide Analysis Identifies Pollution-Sensitive Loci in Fibrotic Interstitial Lung Disease
Gillian C Goobie, Najmeh Assadinia, Chen Xi Yang, et al.
Blood
|
April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Blood
|
February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma
Catherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology
|
August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
Page
of 13